NASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis $97.17 +0.02 (+0.02%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$96.97▼$97.7350-Day Range$96.68▼$98.4552-Week Range$89.55▼$98.95Volume495,025 shsAverage Volume328,482 shsMarket Capitalization$3.18 billionP/E RatioN/ADividend YieldN/APrice Target$100.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amedisys alerts: Email Address Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside3.6% Upside$100.67 Price TargetShort InterestBearish5.12% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.45Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth8.15%From $4.66 to $5.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector481st out of 910 stocksHome Health Care Services Industry4th out of 8 stocks 1.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageAmedisys has only been the subject of 3 research reports in the past 90 days.Read more about Amedisys' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.12% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Amedisys has recently increased by 1.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 1.9 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Amedisys this week, compared to 3 articles on an average week.Search Interest2 people have searched for AMED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amedisys' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 8.15% in the coming year, from $4.66 to $5.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is -151.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is -151.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Amedisys' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesSeptember 6 at 3:31 AM | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Given Consensus Rating of "Hold" by BrokeragesAugust 28, 2024 | msn.comIC Group hosts 5th annual Sunset Senior Fair, connecting seniors with vital resourcesSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 21, 2024 | tmcnet.comnVoq Accelerates HIPAA-Compliant Clinical Documentation Across Multiple Devices with Addition of Mobile Voice for iOSAugust 21, 2024 | globenewswire.comContessa Selected by Centers for Medicare & Medicaid Services to Test Medicare Dementia Care ModelAugust 17, 2024 | finance.yahoo.comHome Healthcare Market to Reach $760.2 Billion, Globally, by 2033 at 10.5% CAGR: Allied Market ResearchAugust 3, 2024 | morningstar.comAmedisys Inc AMEDAugust 1, 2024 | msn.comDeutsche Bank Downgrades Amedisys (AMED)September 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 29, 2024 | markets.businessinsider.comAmedisys: Hold Rating Affirmed Amidst Modest EBITDA Adjustments and Acquisition OfferJuly 24, 2024 | gurufocus.comAmedisys Inc (AMED) Q2 2024 Earnings: EPS of $0.98 Misses Estimates, Revenue of $591. ...July 24, 2024 | globenewswire.comAmedisys Reports Second Quarter 2024 Financial ResultsJuly 23, 2024 | lse.co.ukAmedisys Share Price (AMED.US)June 9, 2024 | seekingalpha.comAmedisys shares could have downside to $74 a share in a no-deal scenario - analystMay 29, 2024 | finance.yahoo.comAREX Capital Management Issues Letter to Enhabit Stockholders Regarding the Need for Dramatic Changes to Board CompositionMay 22, 2024 | msn.comNurse charged with stealing pills while taking care of hospice patientMay 20, 2024 | msn.comAmedisys gains amid report about status of DOJ review of UnitedHealth dealMay 8, 2024 | msn.comAmedisys gains amid report of sweetened divestiture offer in UnitedHealth dealSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/24/2024Today9/07/2024Next Earnings (Estimated)10/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees19,000Year Founded1982Price Target and Rating Average Stock Price Target$100.67 High Stock Price Target$101.00 Low Stock Price Target$100.00 Potential Upside/Downside+3.6%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E Ratio20.85 P/E Growth1.92Net Income$-9,750,000.00 Net Margins4.02% Pretax Margin6.27% Return on Equity12.39% Return on Assets6.78% Debt Debt-to-Equity Ratio0.30 Current Ratio1.16 Quick Ratio1.16 Sales & Book Value Annual Sales$2.29 billion Price / Sales1.39 Cash Flow$6.06 per share Price / Cash Flow16.03 Book Value$36.01 per share Price / Book2.70Miscellaneous Outstanding Shares32,677,000Free Float32,089,000Market Cap$3.18 billion OptionableOptionable Beta0.79 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 53)Chief People Officer Mr. Francis MayerSenior Vice President of DevelopmentKey CompetitorsLHC GroupNASDAQ:LHCGDaVitaNYSE:DVAChemedNYSE:CHER1 RCMNASDAQ:RCMCorVelNASDAQ:CRVLView All CompetitorsInstitutional OwnershipMaven Securities LTDBought 14,700 shares on 8/29/2024Ownership: 0.000%Cetera Investment AdvisersBought 4,773 shares on 8/22/2024Ownership: 0.070%Water Island Capital LLCSold 1,837 shares on 8/16/2024Ownership: 2.148%Creative PlanningBought 295 shares on 8/16/2024Ownership: 0.013%Algert Global LLCBought 3,292 shares on 8/16/2024Ownership: 0.010%View All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions How have AMED shares performed this year? Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED stock has increased by 2.2% and is now trading at $97.17. View the best growth stocks for 2024 here. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Wednesday, July, 24th. The health services provider reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.22 by $0.10. The health services provider earned $591.19 million during the quarter, compared to analyst estimates of $579.34 million. Amedisys had a net margin of 4.02% and a trailing twelve-month return on equity of 12.39%. What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. Who are Amedisys' major shareholders? Top institutional investors of Amedisys include Alpine Associates Management Inc. (3.92%), Mackenzie Financial Corp (2.28%), Water Island Capital LLC (2.15%) and Pentwater Capital Management LP. Insiders that own company stock include David L Kemmerly, Denise M Bohnert, Michael Paul North and Richard A Lechleiter. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC) and QUALCOMM (QCOM). This page (NASDAQ:AMED) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amedisys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
